AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23780502 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Number of subjects: 76
Study 21036743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and bevacizumab plus irinotecan (CBI)
Number of subjects: 65
Study 21036743 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab and bevacizumab (CB)
Number of subjects: 65
Study 21036743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cetuximab and bevacizumab (CB)
Number of subjects: 65
Study 18245934 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) for at least 6 hours per day
Number of subjects: 110
Study 18245934 — intervention group
Group type: COMPARATOR
Intervention: Standard care (incubator or open care system)
Number of subjects: 110
Study 18245934 — intervention group
Group type: EXPERIMENTAL
Intervention: KMC
Number of subjects: 110
Study 16785774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity light treatment
Number of subjects: 63
Study 16785774 — intervention group
Group type: COMPARATOR
Intervention: Medium-intensity light treatment
Number of subjects: 63
Study 15582309 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel for 2 to 3 h
Number of subjects: 2159
Study 15582309 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel for 3 to 6 h
Number of subjects: 2159
Study 15582309 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel for 6 to 12 h
Number of subjects: 2159
Study 15582309 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel for >12 h
Number of subjects: 2159
Study 15582309 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 2159
Study 15582309 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2159
Study 11179984 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily + Amoxicillin 750 mg twice daily
Number of subjects: 165
Study 11179984 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg twice daily + Placebo
Number of subjects: 165
Study 9067694 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (microemulsion oral formulation of cyclosporine A)
Number of subjects: 5
Study 9067694 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune SGC (oral cyclosporine A preparation)
Number of subjects: 5
Study 8453694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (1.5 g/m2)
Number of subjects: 135
Study 8453694 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide (5 g/m2)
Number of subjects: 135
Study 3544649 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg buprenorphine epidurally
Number of subjects: 45
Study 3544649 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg buprenorphine epidurally
Number of subjects: 45
Study 31874865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management in addition to usual practice (restrictive diet, physical activity, and thermal spa treatment)
Number of subjects: 140
Study 31874865 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (restrictive diet, physical activity, and thermal spa treatment)
Number of subjects: 140
Study 29415787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 10 mg
Number of subjects: 0
Study 29415787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 15 mg
Number of subjects: 0
Study 29415787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 0
Study 27459533 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 16
Study 27459533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27459533 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (80 mg twice daily)
Number of subjects: 16
Study 24825262 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU of oral vitamin D3 (Group 1; n=38)
Number of subjects: 76
Study 24825262 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 IU of oral vitamin D3 (Group 2; n=38)
Number of subjects: 76
Study 24825262 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 76
Study 22979913 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2% mouthwash
Number of subjects: 60
Study 22979913 — intervention group
Group type: COMPARATOR
Intervention: Herbal mouth wash
Number of subjects: 60
Study 20616970 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-directed intervention (CDI) including vitamin A supplementation, insecticide-treated nets, home management of malaria, and short-course, directly-observed treatment for tuberculosis patients.
Number of subjects: 35
Study 20616970 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-directed intervention (CDI) for all five interventions.
Number of subjects: 35
Study 20616970 — intervention group
Group type: COMPARATOR
Intervention: Comparison districts (control) with other delivery approaches.
Number of subjects: 35
Study 18396744 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mL of NaP (two 40 mL doses separated by 24 h)
Number of subjects: 182
Study 18396744 — intervention group
Group type: COMPARATOR
Intervention: Standard 4‐liters PEG
Number of subjects: 182
Study 11889278 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention for nine weeks
Number of subjects: 111
Study 11889278 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention for nine weeks
Number of subjects: 111
Study 11889278 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 111
Study 9451677 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 0
Study 9451677 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedies < 12C
Number of subjects: 0
Study 9451677 — intervention group
Group type: COMPARATOR
Intervention: Homeopathic remedies >= 12C
Number of subjects: 0
Study 9451677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8204351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rate (0.38 Gy/h)
Number of subjects: 155
Study 8204351 — intervention group
Group type: COMPARATOR
Intervention: High dose rate (0.73 Gy/h)
Number of subjects: 155
Study 3653228 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenously (i.v.) of ranitidine HCl
Number of subjects: 6
Study 3653228 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg orally of ranitidine HCl
Number of subjects: 6
Study 31735684 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry and deep breathing exercise (DBE)
Number of subjects: 90
Study 31735684 — intervention group
Group type: COMPARATOR
Intervention: Deep breathing exercise (DBE) only
Number of subjects: 90
Study 29392332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (10 Hz, 10 sessions)
Number of subjects: 12
Study 29392332 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 12
Study 28915863 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (3 months supervised exercise 2 times per week followed by 12 months active follow-up)
Number of subjects: 219
Study 28915863 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + diet intervention (exercise training with additional dietary counseling, 12 sessions over 15 months by a renal dietician)
Number of subjects: 219
Study 28915863 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 219
Study 26613214 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prophylactic INSURE with surfactant administration immediately after birth
Number of subjects: 80
Study 26613214 — intervention group
Group type: COMPARATOR
Intervention: Later prophylactic INSURE with surfactant administration at the 15th minute after birth
Number of subjects: 80
Study 26613214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 23159770 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα‐2b (0.5 μg/kg/week)
Number of subjects: 540
Study 23159770 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 540
Study 20851617 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive harvested grafts
Number of subjects: 200
Study 20851617 — intervention group
Group type: COMPARATOR
Intervention: Conventionally harvested grafts
Number of subjects: 200
Study 18198263 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial fibrinogen level
Number of subjects: 314
Study 18198263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower FEV1
Number of subjects: 314
Study 18198263 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of prestudy severe exacerbations
Number of subjects: 314
Study 18198263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Dlco
Number of subjects: 314
Study 18198263 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of prestudy moderate exacerbations
Number of subjects: 314
Study 17163300 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon‐alpha‐2a (IFNalpha‐2a)
Number of subjects: 186
Study 17163300 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon‐alpha‐2b (IFNalpha‐2b)
Number of subjects: 186
Study 12679210 — intervention group
Group type: COMPARATOR
Intervention: Stress perfusion scintigraphy (SPS), n = 35
Number of subjects: 70
Study 12679210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR), n = 35
Number of subjects: 70
Study 10739429 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (tryptophan-free amino acid drink)
Number of subjects: 32
Study 10739429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced mixture of amino acids)
Number of subjects: 32
Study 9370031 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment therapy (performed at baseline and repeated every 6 months as needed)
Number of subjects: 123
Study 9370031 — intervention group
Group type: COMPARATOR
Intervention: Mock adjustments (control group)
Number of subjects: 123
Study 1396808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 46
Study 1396808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echocardiography
Number of subjects: 46
Study 30740765 — intervention group
Group type: EXPERIMENTAL
Intervention: STOMA psychosocial intervention programme
Number of subjects: 53
Study 30740765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 29175276 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR therapy
Number of subjects: 150
Study 29175276 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 150
Study 26985045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation during saline infusion
Number of subjects: 100
Study 26985045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation during naloxone infusion
Number of subjects: 100
Study 26985045 — intervention group
Group type: COMPARATOR
Intervention: Control group with saline infusion
Number of subjects: 100
Study 26985045 — intervention group
Group type: COMPARATOR
Intervention: Control group with naloxone infusion
Number of subjects: 100
Study 25033643 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic drug treatment
Number of subjects: 120
Study 25033643 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing interventions
Number of subjects: 120
Study 25033643 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention and analgesic drug treatment
Number of subjects: 120
Study 25033643 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing methods
Number of subjects: 120
Study 22340260 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-836 (0.06 mg/kg)
Number of subjects: 18
Study 22340260 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-836 (0.08 mg/kg)
Number of subjects: 18
Study 22340260 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-836 (0.1 mg/kg)
Number of subjects: 18
Study 22340260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22340260 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-836
Number of subjects: 18
Study 18823760 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 36385
Study 18823760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36385
Study 18823760 — intervention group
Group type: COMPARATOR
Intervention: Probability of receiving placebo
Number of subjects: 36385
Study 18823760 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline severity
Number of subjects: 36385
Study 18823760 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of publication
Number of subjects: 36385
Study 18823760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed versus flexible dose design
Number of subjects: 36385
Study 18823760 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial duration
Number of subjects: 36385
Study 18823760 — intervention group
Group type: EXPERIMENTAL
Intervention: Population age
Number of subjects: 36385
Study 17922880 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR Insulin after 4-week smoking abstinence
Number of subjects: 24
Study 17922880 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR Insulin after smoking one cigarette (without NRT)
Number of subjects: 24
Study 17922880 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR Insulin after 4-week smoking abstinence with NRT
Number of subjects: 24
Study 17922880 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR Insulin after smoking one cigarette with NRT
Number of subjects: 24
Study 15935962 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft mat without stabilised surface
Number of subjects: 6
Study 15935962 — intervention group
Group type: EXPERIMENTAL
Intervention: Mats with surface stabilising interface
Number of subjects: 6
Study 14508022 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled saline with suggestion of bronchoconstriction
Number of subjects: 17
Study 14508022 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled saline with suggestion of bronchodilation
Number of subjects: 17
Study 14508022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham bronchoconstrictor
Number of subjects: 17
Study 10934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Response Program (QRP) services
Number of subjects: 155
Study 10934538 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care services
Number of subjects: 155
Study 8522052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (initial dose of 7.2 +/- 0.1 mg.kg-1.day-1, decreased stepwise and interrupted after 6-62 months)
Number of subjects: 130
Study 8522052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 130
Study 8522052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 1815339 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin dosed twice daily
Number of subjects: 131
Study 1815339 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin dosed three times daily
Number of subjects: 131
Study 6384419 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 74
Study 6384419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 29673262 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy with exercise
Number of subjects: 110
Study 29673262 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulative therapy without exercise
Number of subjects: 110
Study 30186593 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT) as an add-on treatment after a single training session for GPs lasting two and a half hours.
Number of subjects: 87
Study 30186593 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group).
Number of subjects: 87
Study 27430386 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-DAG
Number of subjects: 19
Study 27430386 — intervention group
Group type: COMPARATOR
Intervention: TAG
Number of subjects: 19
Study 24828024 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ supplementation (20 μg/d)
Number of subjects: 1122
Study 24828024 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 1122
Study 22432107 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 259
Study 22432107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 19269127 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorite-place group (visited favorite places at least once per day on 5 weekdays)
Number of subjects: 0
Study 19269127 — intervention group
Group type: COMPARATOR
Intervention: Not-visiting group (visited favorite place 0-1 times)
Number of subjects: 0
Study 19269127 — intervention group
Group type: COMPARATOR
Intervention: Control group (given instructions that did not mention favorite places)
Number of subjects: 0
Study 17505374 — intervention group
Group type: EXPERIMENTAL
Intervention: LoFric catheter
Number of subjects: 196
Study 17505374 — intervention group
Group type: COMPARATOR
Intervention: SpeediCath catheter
Number of subjects: 196
Study 15104324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IPPMG Hospital
Number of subjects: 5
Study 15104324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IFF Hospital (Room 1)
Number of subjects: 5
Study 15104324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IFF Hospital (Room 2)
Number of subjects: 5
Study 15104324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, IFF Hospital (Mobile Equipment)
Number of subjects: 5
Study 15104324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, Omdurman Hospital
Number of subjects: 5
Study 15104324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, Khartoum Hospital
Number of subjects: 5
Study 15104324 — intervention group
Group type: EXPERIMENTAL
Intervention: Postero-anterior (PA) projection, age interval 1-5 years, Ahmed Gasim Hospital
Number of subjects: 5
Study 11668667 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg CCK-4 during REM sleep
Number of subjects: 15
Study 11668667 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg CCK-4 during delta sleep
Number of subjects: 15
Study 11668667 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg CCK-4 during REM sleep
Number of subjects: 15
Study 11668667 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg CCK-4 during delta sleep
Number of subjects: 15
Study 11668667 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 during delta sleep
Number of subjects: 15
Study 9830891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bow method
Number of subjects: 222
Study 9830891 — intervention group
Group type: COMPARATOR
Intervention: Knot method
Number of subjects: 222
Study 9830891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 222
Study 7862896 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol mixed into a drink of caffeine-free cola
Number of subjects: 44
Study 7862896 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 44
Study 7862896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol and stress combined
Number of subjects: 44
Study 7862896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol and stress
Number of subjects: 44
Study 2510266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 115
Study 2510266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 1102259 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg daily
Number of subjects: 23
Study 1102259 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg daily
Number of subjects: 23
Study 1102259 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 100 mg daily
Number of subjects: 23
Study 31539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative volume replacement therapy (VRT) - 1 ml/kg/h of Hartmann's solution for 12 hours
Number of subjects: 169
Study 31539025 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 169
Study 31539025 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative volume replacement therapy (VRT)
Number of subjects: 169
Study 31398361 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min)
Number of subjects: 30
Study 31398361 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 28484817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen Torch Transillumination (PTI)
Number of subjects: 69
Study 28484817 — intervention group
Group type: EXPERIMENTAL
Intervention: Veinlite® EMS (TransLite®, Texas, USA)
Number of subjects: 69
Study 28484817 — intervention group
Group type: COMPARATOR
Intervention: Conventional venepuncture (control)
Number of subjects: 69
Study 26380441 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmailong Injection (100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days)
Number of subjects: 238
Study 26380441 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmailong Injection
Number of subjects: 238
Study 26380441 — intervention group
Group type: COMPARATOR
Intervention: Control group (XI mimetic agent, 100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days)
Number of subjects: 238
Study 24377214 — intervention group
Group type: EXPERIMENTAL
Intervention: Three therapies of strong stimulation (strong pricking therapy, strong cupping therapy, strong moxibustion)
Number of subjects: 80
Study 24377214 — intervention group
Group type: COMPARATOR
Intervention: Half-needling technique combined with moxa stick therapy
Number of subjects: 80
Study 22032936 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive picture‐word cues
Number of subjects: 0
Study 22032936 — intervention group
Group type: COMPARATOR
Intervention: Negative picture‐word cues
Number of subjects: 0